The News

U.S patent & trademark office issues patent no 6,830,584 to CoreValve for its 'device for replacing a cardiac valve by percutaneous route'

19/01/2005

“This event represents another landmark in validating our ReValving system as the next-generation cath lab therapy for interventional cardiology.” Jacques Séguin, MD, PhD Chairman, CEO and Founder, CoreValve, S.A.

PARIS and IRVINE, Calif., Jan. 19, 2005—CoreValve S.A. announced today that the United States Patent & Trademark Office has issued Patent No. 6,830,584 to CoreValve, thus protecting the Company’s ‘device for replacing a cardiac valve by percutaneous route’—i.e., the CoreValve Percutaneous ReValving System™.

With ReValving™, heart valve replacement can be performed ‘non-surgically’ in a cardiac ‘cath lab’ just like angioplasty and stenting, resulting in less trauma to the patient and substantial cost-savings to the healthcare system compared to open-heart surgery to replace diseased heart valves.

“U.S. patent protection for ReValving is critically important, of course—particularly in light of the fact that we already have clinically established that ReValving is feasible to non-surgically treat the widest possible range of diseased heart-valve patients, including traditional surgical-candidates,” said Jacques Séguin, M.D., chairman and CEO of CoreValve. “Indeed, CoreValve’s ReValving approach has potential universal applicability to percutaneously treat the two most prevalent diseases of the aortic valve—stenosis and regurgitation,” added Professor Séguin.

About CoreValve
Privately held CoreValve, S.A., headquartered in Paris, France, has developed a proprietary delivery system for percutaneous heart valve replacement, based on a novel catheter-and-selfexpanding- stent approach on a beating heart, thus avoiding open-heart surgery. The CoreValve procedure—with the proprietary CoreValve Percutaneous ReValving System™—can be performed in a cardiac “cath lab” just like angioplasty and stenting, resulting in less trauma to the patient and substantial cost-savings to the healthcare system.

This news release contains certain “forward-looking” statements under the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements, which may include, but are not limited to, statements concerning the projections, financial condition, results of operations and businesses of CoreValve, are based on management’s current expectations and estimates and involve risks anduncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements. Factors that could cause or contribute to such differences may include, but are not limited to, risks relating to the protection of intellectual property, changes to governmental regulation of medical devices, the FDA’s approval of new products, the impact of competitive products, changes to the competitive environment, the acceptance of new products in the market, conditions of the interventionalcardiology industry and the economy and other factors.